Highly specific and potently activating Vγ9Vδ2-T cell specific nanobodies for diagnostic and therapeutic applications

被引:26
作者
de Bruin, Renee C. G. [1 ]
Lougheed, Sinead M. [1 ]
van der Kruk, Liza [1 ]
Stam, Anita G. [1 ]
Hooijberg, Erik [2 ]
Roovers, Rob C. [3 ]
Henegouwen, Paul M. P. van Bergen En [3 ]
Verheul, Henk M. W. [1 ]
de Gruijl, Tanja D. [1 ]
van der Vliet, Hans J. [1 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, Room 3A38,De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Pathol, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands
[3] Univ Utrecht, Fac Sci, Dept Cell Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands
关键词
Nanobody; Single-domain antibody fragment; VHH; Gamma delta T cells; Flow cytometry; MACS; Immunocytochemistry; Immunotherapy; Cancer; DELTA T-CELLS; CANCER-IMMUNOTHERAPY; ANTIBODY FRAGMENTS; ANTIGEN RECEPTOR; ALBUMIN-BINDING; LIGHT-CHAINS; RECOGNITION; DOMAIN; PHOSPHOANTIGENS; MODULATION;
D O I
10.1016/j.clim.2016.06.012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
V gamma 9V delta 2-T cells constitute the predominant subset of gamma delta-T cells in human peripheral blood and have been shown to play an important role in antimicrobial and antitumor immune responses. Several efforts have been initiated to exploit these cells for cancer immunotherapy, e.g. by using phosphoantigens, adoptive cell transfer, and by a bispecific monoclonal antibody based approach. Here, we report the generation of a novel set of V gamma 9V delta 2-T cell specific VHH (or nanobody). VHH have several advantages compared to conventional antibodies related to their small size, stability, ease of generating multispecific molecules and low immunogenicity. With high specificity and affinity, the anti-V gamma 9V delta 2-T cell receptor VHHs are shown to be useful for FACS, MACS and immunocytochemistry. In addition, some VHH were found to specifically activate V gamma 9V delta 2-T cells. Besides being of possible immunotherapeutic value, these single domain antibodies will be of great value in the further study of this important immune effector cell subset. (C) 2016 The Authors. Published by Elsevier Inc.
引用
收藏
页码:128 / 138
页数:11
相关论文
共 35 条
[21]   The Molecular Basis for Modulation of Human Vγ9Vδ2 T Cell Responses by CD277/Butyrophilin-3 (BTN3A)-specific Antibodies [J].
Palakodeti, Aparna ;
Sandstrom, Andrew ;
Sundaresan, Lakshmi ;
Harly, Christelle ;
Nedellec, Steven ;
Olive, Daniel ;
Scotet, Emmanuel ;
Bonneville, Marc ;
Adams, Erin J. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (39) :32780-32790
[22]   Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies [J].
Roovers, Rob C. ;
Laeremans, Toon ;
Huang, Lieven ;
De Taeye, Severine ;
Verkleij, Arie J. ;
Revets, Hilde ;
de Haard, Hans J. ;
van Bergen en Henegouwen, Paul M. P. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (03) :303-317
[23]   The Intracellular B30.2 Domain of Butyrophilin 3A1 Binds Phosphoantigens to Mediate Activation of Human Vγ9Vδ2 T Cells [J].
Sandstrom, Andrew ;
Peigne, Cassie-Marie ;
Leger, Alexandra ;
Crooks, James E. ;
Konczak, Fabienne ;
Gesnel, Marie-Claude ;
Breathnach, Richard ;
Bonneville, Marc ;
Scotet, Emmanuel ;
Adams, Erin J. .
IMMUNITY, 2014, 40 (04) :490-500
[24]   Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α [J].
Schneiders, Famke L. ;
de Bruin, Renee C. G. ;
Santegoets, Saskia J. A. M. ;
Bonneville, Marc ;
Scotet, Emmanuel ;
Scheper, Rik J. ;
Verheul, Henk M. W. ;
de Gruijl, Tanja D. ;
van der Vliet, Hans J. .
CLINICAL IMMUNOLOGY, 2012, 142 (02) :194-200
[25]   Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells [J].
Scholten, KBJ ;
Kramer, D ;
Kueter, EWM ;
Graf, M ;
Schoedl, T ;
Meijer, CJLM ;
Schreurs, MWJ ;
Hooijberg, E .
CLINICAL IMMUNOLOGY, 2006, 119 (02) :135-145
[26]   Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer [J].
Scholten, KBJ ;
Schreurs, MWJ ;
Ruizendaal, JJ ;
Kueter, EWM ;
Kramer, D ;
Veenbergen, S ;
Meijer, CJLM ;
Hooijberg, E .
CLINICAL IMMUNOLOGY, 2005, 114 (02) :119-129
[27]   Synthetic phosphoantigens enhance human Vγ9Vδ2 T lymphocytes killing of non-Hodgkin's B lymphoma [J].
Sicard, H ;
Al Saati, T ;
Delsol, G ;
Fournié, JJ .
MOLECULAR MEDICINE, 2001, 7 (10) :711-722
[28]   Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology [J].
Tijink, Bernard M. ;
Laeremans, Toon ;
Budde, Marianne ;
Walsum, Marijke Stigter-van ;
Dreier, Torsten ;
de Haard, Hans J. ;
Leemans, C. Rene ;
van Dongen, Guus A. M. S. .
MOLECULAR CANCER THERAPEUTICS, 2008, 7 (08) :2288-2297
[29]  
Transue TR, 1998, PROTEINS, V32, P515, DOI 10.1002/(SICI)1097-0134(19980901)32:4<515::AID-PROT9>3.0.CO
[30]  
2-E